Irinotecan News and Research

RSS
Irinotecan hydrochloride is approved by the Food and Drug Administration (FDA) to be used with other drugs to treat colorectal cancer that has metastasized (spread to other parts of the body). It is also approved to treat metastatic colorectal cancer that has recurred (come back) or gotten worse after earlier chemotherapy. In addition to the uses that have been approved by the FDA, irinotecan hydrochloride is sometimes used to treat other types of cancer. Irinotecan hydrochloride is also being studied in the treatment of other types of cancer.
patients with KRAS wild-type MCRC can benefit from Cetuximab Or Bevacizumab With Combi Chemo Equivalent For patients with KRAS wild-type MCRC

patients with KRAS wild-type MCRC can benefit from Cetuximab Or Bevacizumab With Combi Chemo Equivalent For patients with KRAS wild-type MCRC

Adding MM-398 to standard treatment improves survival in metastatic pancreatic cancer patients

Adding MM-398 to standard treatment improves survival in metastatic pancreatic cancer patients

New drug shows promising results in patients with advanced pancreatic cancer

New drug shows promising results in patients with advanced pancreatic cancer

Patients with advanced colorectal cancer respond well to new combination therapy

Patients with advanced colorectal cancer respond well to new combination therapy

Amgen presents extended analysis of PEAK study data at ASCO

Amgen presents extended analysis of PEAK study data at ASCO

Amrubicin promise for etoposide-naïve SCLC patients

Amrubicin promise for etoposide-naïve SCLC patients

Kinex receives FDA allowance for Oratecan anti-cancer drug irinotecan with enhanced oral absorption

Kinex receives FDA allowance for Oratecan anti-cancer drug irinotecan with enhanced oral absorption

Amrubicin regimen inferior to irinotecan for extensive SCLC

Amrubicin regimen inferior to irinotecan for extensive SCLC

Tgen professor to receive 2014 Hope Funds Award for developing numerous cancer treatments

Tgen professor to receive 2014 Hope Funds Award for developing numerous cancer treatments

Dr. Daniel D. Von Hoff named one of ASCO's 50 Oncology Luminaries

Dr. Daniel D. Von Hoff named one of ASCO's 50 Oncology Luminaries

Bayer enrolls patients for Phase III trial of Stivarga (regorafenib) tablets in colorectal cancer

Bayer enrolls patients for Phase III trial of Stivarga (regorafenib) tablets in colorectal cancer

Researchers find biological weakness in the workings of mutated gene involved in human cancers

Researchers find biological weakness in the workings of mutated gene involved in human cancers

Etoposide plus cisplatin remains best for limited-stage SCLC

Etoposide plus cisplatin remains best for limited-stage SCLC

Agenus' Prophage vaccine Phase 2 study hailed in Neuro-Oncology journal

Agenus' Prophage vaccine Phase 2 study hailed in Neuro-Oncology journal

Research confirms superior antitumor activity of novel anticancer agent FL118

Research confirms superior antitumor activity of novel anticancer agent FL118

European Commission approves update of Erbitux  to treat patients with RAS wild-type mCRC

European Commission approves update of Erbitux to treat patients with RAS wild-type mCRC

Neuro-Oncology publishes promising phase 2 results from Agenus’ brain cancer vaccine study

Neuro-Oncology publishes promising phase 2 results from Agenus’ brain cancer vaccine study

CRAB CTC enrolls first patient into inaugural cancer clinical trial

CRAB CTC enrolls first patient into inaugural cancer clinical trial

SillaJen executes definitive merger agreement to acquire Jennerex

SillaJen executes definitive merger agreement to acquire Jennerex

Research paves way towards personalized chronotherapy treatments

Research paves way towards personalized chronotherapy treatments